{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:35:34Z","timestamp":1793352934903,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jtha.2026.08.001","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:41:46Z","timestamp":1786084906000},"page":"3811-3823","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacology of anticoagulants: from heparin to novel target-specific agents"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-7055","authenticated-orcid":false,"given":"Surasak","family":"Wichaiyo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.08.001_bib1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40138-013-0014-6","article-title":"Anticoagulants: a review of the pharmacology, dosing, and complications","volume":"1","author":"Alquwaizani","year":"2013","journal-title":"Curr Emerg Hospital Med Rep"},{"key":"10.1016\/j.jtha.2026.08.001_bib2","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11239-016-1363-2","article-title":"Erratum to: Pharmacology of anticoagulants used in the treatment of venous thromboembolism","volume":"42","author":"Nutescu","year":"2016","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.08.001_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and cons of new oral anticoagulants","volume":"2013","author":"Bauer","year":"2013","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2026.08.001_bib4","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1634\/theoncologist.2013-0239","article-title":"New oral anticoagulants and the cancer patient","volume":"19","author":"Short","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.08.001_bib5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1021\/acsptsci.3c00052","article-title":"Determination of the potential clinical benefits of small molecule factor XIa inhibitors in arterial thrombosis","volume":"6","author":"Wichaiyo","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.jtha.2026.08.001_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/ATVBAHA.116.308595","article-title":"Factor XII as a therapeutic target in thromboembolic and inflammatory diseases","volume":"37","author":"Nickel","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2026.08.001_bib7","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1080\/13543776.2021.1945580","article-title":"Factor XII(a) inhibitors: a review of the patent literature","volume":"31","author":"Kalinin","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.jtha.2026.08.001_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111561","article-title":"Pharmacological and clinical application of heparin progress: an essential drug for modern medicine","volume":"139","author":"Qiu","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jtha.2026.08.001_bib9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2174\/1567201054367968","article-title":"Gastrointestinal absorption of heparin by lipidization or coadministration with penetration enhancers","volume":"2","author":"Ross","year":"2005","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.jtha.2026.08.001_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.95.1.118","article-title":"Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate","volume":"95","author":"Cosmi","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib11","doi-asserted-by":"crossref","first-page":"e771","DOI":"10.1161\/CIR.0000000000001328","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"151","author":"Rao","year":"2025","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib12","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.001_bib13","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtha.2026.08.001_bib14","article-title":"2026 AHA\/ACC\/ACCP\/ACEP\/CHEST\/SCAI\/SHM\/SIR\/SVM\/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"153","author":"Creager","year":"2026","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1352982","article-title":"Unlocking the potential of fondaparinux: guideline for optimal usage and clinical suggestions (2023)","volume":"15","author":"Yin","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.001_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000000932","article-title":"Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach","volume":"35","author":"Ambati","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jtha.2026.08.001_bib17","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2016-11-709873","article-title":"Heparin-induced thrombocytopenia","volume":"129","author":"Arepally","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.001_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1358863X19898253","article-title":"Heparin-induced thrombocytopenia (HIT): review of incidence, diagnosis, and management","volume":"25","author":"Hogan","year":"2020","journal-title":"Vasc Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib19","doi-asserted-by":"crossref","first-page":"e584","DOI":"10.1093\/ajhp\/zxae109","article-title":"The efficacy and safety of direct oral anticoagulants in the treatment of the acute phase of heparin-induced thrombocytopenia: a systematic review","volume":"81","author":"Sadowski","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.jtha.2026.08.001_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2000-9497","article-title":"Comparative pharmacokinetics of LMWHs","volume":"26","author":"Samama","year":"2000","journal-title":"Semi Thromb Hemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib21","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1007\/s00228-022-03365-4","article-title":"Tinzaparin\u2014a review of its molecular profile, pharmacology, special properties, and clinical uses","volume":"78","author":"Amerali","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.001_bib22","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2165\/00003495-199244050-00010","article-title":"Nadroparin calcium","volume":"44","author":"Barradell","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.jtha.2026.08.001_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-2-21","article-title":"Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance?","volume":"2","author":"Johansen","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jtha.2026.08.001_bib24","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s00228-022-03344-9","article-title":"Therapeutically dosed low molecular weight heparins in renal impairment: a nationwide survey","volume":"78","author":"Jaspers","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.001_bib25","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.001_bib26","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.001_bib27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.mcna.2025.02.003","article-title":"Venous thromboembolism prevention in the hospitalized medical patient","volume":"109","author":"Tsaftaridis","year":"2025","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.jtha.2026.08.001_bib28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.08.001_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.966754","article-title":"Evaluating the immunogenicity of heparin and heparin derivatives by measuring their binding to platelet factor 4 using biolayer interferometry","volume":"9","author":"Chen","year":"2022","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jtha.2026.08.001_bib30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jtha.2025.01.009","article-title":"Basics of diagnosis and treatment of venous thromboembolism","volume":"23","author":"Cox","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib31","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/bcp.13663","article-title":"Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis","volume":"84","author":"Zufferey","year":"2018","journal-title":"Brit J Clin Pharm"},{"key":"10.1016\/j.jtha.2026.08.001_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0049-3848(03)00030-6","article-title":"Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux)","volume":"109","author":"Samama","year":"2003","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.001_bib33","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood-2014-03-559518","article-title":"Binding of anti-platelet factor 4\/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4","volume":"124","author":"Kreimann","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.001_bib34","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1182\/blood-2005-05-1938","article-title":"Anti-platelet factor 4\/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin","volume":"106","author":"Warkentin","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.001_bib35","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1182\/blood-2011-11-376293","article-title":"How I treat heparin-induced thrombocytopenia","volume":"119","author":"Cuker","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.001_bib36","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.001_bib37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2133\/dmpk.DMPK-10-RG-059","article-title":"Pharmacokinetic and pharmacodynamic variation associated with VKORC1 and CYP2C9 polymorphisms in Thai patients taking warfarin","volume":"25","author":"Sangviroon","year":"2010","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.08.001_bib39","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.08.001_bib40","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.recesp.2025.07.008","volume":"79","author":"Vivas","year":"2026","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jtha.2026.08.001_bib41","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2200322","article-title":"Perioperative management of anticoagulant and antiplatelet therapy","volume":"2","author":"Douketis","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jtha.2026.08.001_bib42","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.1097\/MS9.0000000000003848","article-title":"Warfarin-induced skin necrosis: a narrative review of clinical features, risk factors, and treatment strategies","volume":"87","author":"Mohamed Osman","year":"2025","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.jtha.2026.08.001_bib43","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1592\/phco.23.5.674.32200","article-title":"Purple toes syndrome associated with warfarin therapy in a patient with antiphospholipid syndrome","volume":"23","author":"Talmadge","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jtha.2026.08.001_bib44","first-page":"88","article-title":"Acenocoumarol\u2014a historical overview and its place in modern anticoagulant therapy","volume":"31","author":"Farandzha","year":"2025","journal-title":"Bulg Cardiol"},{"key":"10.1016\/j.jtha.2026.08.001_bib45","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3390\/pharmaceutics18020163","article-title":"An overview of anticoagulant drugs pharmacology, therapeutic approaches, limitations and perspectives","volume":"18","author":"Morgovan","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jtha.2026.08.001_bib46","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCRESAHA.112.276741","article-title":"Oral direct factor Xa inhibitors","volume":"111","author":"Yeh","year":"2012","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2026.08.001_bib47","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1056\/NEJMra1011670","article-title":"The hemostatic system as a modulator of atherosclerosis","volume":"364","author":"Borissoff","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1093\/cvr\/cvt343","article-title":"Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants","volume":"101","author":"Spronk","year":"2014","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jtha.2026.08.001_bib49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","article-title":"Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1","volume":"126","author":"Petzold","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.jtha.2026.08.001_bib50","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1160\/TH10-02-0097","article-title":"Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin","volume":"104","author":"Wong","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.thromres.2016.02.028","article-title":"Edoxaban, a direct factor Xa inhibitor, suppresses tissue-factor induced human platelet aggregation and clot-bound factor Xa in vitro: comparison with an antithrombin-dependent factor Xa inhibitor, fondaparinux","volume":"141","author":"Honda","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.001_bib52","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.12610","article-title":"Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives","volume":"95","author":"G\u00f3mez-Outes","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.08.001_bib53","doi-asserted-by":"crossref","first-page":"9S","DOI":"10.1177\/1076029609343004","article-title":"Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor","volume":"15","author":"Stangier","year":"2009","journal-title":"Clin Appl Thromb\/Hemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib54","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib55","article-title":"Bleeding risk of direct oral anticoagulants in patients with heart failure and atrial fibrillation","volume":"14","author":"Jackevicius","year":"2021","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1016\/j.jtha.2026.08.001_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ajgsup.2016.3","article-title":"Incidence and clinical presentation of gastrointestinal bleeding in atrial fibrillation patients taking direct oral anticoagulants","volume":"3","author":"Desai","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jtha.2026.08.001_bib57","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1161\/CIRCULATIONAHA.115.019628","article-title":"Idarucizumab","volume":"132","author":"Eikelboom","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib58","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.jacc.2016.01.043","article-title":"Restarting dabigatran etexilate 24 h after reversal with idarucizumab and redosing idarucizumab in healthy volunteers","volume":"67","author":"Glund","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.08.001_bib59","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.2147\/DDDT.S203112","article-title":"Dabigatran must be used carefully: literature review and recommendations for management of adverse events","volume":"13","author":"Lin","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jtha.2026.08.001_bib60","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000515","article-title":"Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials","volume":"3","author":"Douxfils","year":"2014","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.08.001_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2018.05.048","article-title":"Increased risk of myocardial infarction with dabigatran etexilate: fact or fiction? A critical meta-analysis of over 580,000 patients from integrating randomized controlled trials and real-world studies","volume":"267","author":"Wei","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jtha.2026.08.001_bib62","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cpdd.26","article-title":"Investigation of pharmacodynamic and pharmacokinetic interactions between rivaroxaban and enoxaparin in healthy male subjects","volume":"2","author":"Kubitza","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jtha.2026.08.001_bib63","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1111\/jth.13801","article-title":"Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study","volume":"15","author":"Kreutz","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib64","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1477-9560-12-22","article-title":"Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism","volume":"12","author":"Harder","year":"2014","journal-title":"Thromb J"},{"key":"10.1016\/j.jtha.2026.08.001_bib65","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/j.jacc.2020.07.070","article-title":"Antithrombotic management of venous thromboembolism","volume":"76","author":"Renner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.08.001_bib66","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1161\/CIRCULATIONAHA.106.668020","article-title":"Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939)","volume":"116","author":"Agnelli","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib67","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s00228-005-0043-5","article-title":"Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939\u2014an oral, direct factor Xa inhibitor\u2014after multiple dosing in healthy male subjects","volume":"61","author":"Kubitza","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.001_bib68","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/jth.13213","article-title":"Comparison between the impact of morning and evening doses of rivaroxaban on the circadian endogenous coagulation rhythm in healthy subjects","volume":"14","author":"Brunner-Ziegler","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.08.001_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007338","article-title":"Evidence gaps in the era of non-vitamin K oral anticoagulants","volume":"7","author":"Aronis","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.08.001_bib70","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ejh.13185","article-title":"Comparative risk of major bleeding with rivaroxaban and warfarin: population-based cohort study of unprovoked venous thromboembolism","volume":"102","author":"Kohn","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2026.08.001_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.034641","article-title":"Risk of major bleeding, stroke\/systemic embolism, and death associated with different oral anticoagulants in patients with atrial fibrillation and severe chronic kidney disease","volume":"13","author":"Xu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jtha.2026.08.001_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.106438","article-title":"Bleeding risk on rivaroxaban versus apixaban in older patients with venous thromboembolism: a nationwide observational register-based study","volume":"142","author":"Roupe","year":"2025","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib73","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib74","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.7326\/M21-1474","article-title":"Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants","volume":"174","author":"Ingason","year":"2021","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1049283","article-title":"Comparative differences in the risk of major gastrointestinal bleeding among different direct oral anticoagulants: an updated traditional and Bayesian network meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.001_bib76","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.thromres.2023.10.013","article-title":"Gastrointestinal bleeding with direct oral anticoagulants in patients with atrial fibrillation and anaemia","volume":"232","author":"Al-Hussainy","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.08.001_bib77","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1055\/s-0038-1649507","article-title":"Mechanistic basis for the differential effects of rivaroxaban and apixaban on global tests of coagulation","volume":"2","author":"Kim","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2026.08.001_bib78","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00210-021-02190-3","article-title":"Coagulation markers in patients with venous thromboembolism treated with 10 mg apixaban twice daily","volume":"395","author":"Ono","year":"2021","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.jtha.2026.08.001_bib79","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1093\/eurheartj\/ehu181","article-title":"Edoxaban: a focused review of its clinical pharmacology","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.001_bib80","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40262-015-0342-7","article-title":"Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral aticoagulant that inhibits clotting factor Xa","volume":"55","author":"Parasrampuria","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jtha.2026.08.001_bib81","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib82","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/STROKEAHA.123.045098","article-title":"Effectiveness and safety of edoxaban compared with apixaban in elderly patients with nonvalvular atrial fibrillation: a real-world population-based cohort study","volume":"55","author":"Chiv","year":"2024","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2026.08.001_bib83","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1093\/eurheartj\/suy016","article-title":"Pharmacological properties of betrixaban","volume":"20","author":"Huisman","year":"2018","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.jtha.2026.08.001_bib84","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3400\/avd.ra.19-00115","article-title":"Recommendations for VTE prophylaxis in medically ill patients","volume":"13","author":"Skeik","year":"2020","journal-title":"Ann Vasc Dis"},{"key":"10.1016\/j.jtha.2026.08.001_bib85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.21037\/cdt-20-859","article-title":"A narrative review of low-dose rivaroxaban in patients with atherothrombotic cardiovascular disease: vascular protection beyond anticoagulation","volume":"11","author":"Rocha","year":"2021","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.jtha.2026.08.001_bib86","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.3324\/haematol.2022.281586","article-title":"Lack of efficacy of direct oral anticoagulants compared to warfarin in antiphospholipid antibody syndrome","volume":"107","author":"Giarretta","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.08.001_bib87","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.08.001_bib88","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.08.001_bib90","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1182\/blood-2024-201421","article-title":"Phase 1 study of the safety and pharmacodynamics of a single dose of Vmx-C001 in healthy subjects with and without FXa direct oral anticoagulants","volume":"144","author":"Short","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.001_bib91","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/21548331.2019.1643728","article-title":"Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists","volume":"47","author":"Desai","year":"2019","journal-title":"Hosp Pract"},{"key":"10.1016\/j.jtha.2026.08.001_bib92","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2024-209118","article-title":"Coagulation factor XII (F12) haploinsufficiency is protective against venous thromboembolism","volume":"144","author":"Haj","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.08.001_bib93","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.3324\/haematol.2023.283682","article-title":"Novel horizons in anticoagulation: the emerging role of factor XI inhibitors across different settings","volume":"109","author":"Cohen","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.08.001_bib94","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1161\/CIRCULATIONAHA.122.062353","article-title":"Pharmacology and clinical development of factor XI inhibitors","volume":"147","author":"Greco","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jtha.2026.08.001_bib95","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.08.001_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112753","article-title":"Factor XII\/XIIa inhibitors: their discovery, development, and potential indications","volume":"208","author":"Davoine","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.jtha.2026.08.001_bib97","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/jth.15130","article-title":"Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection","volume":"19","author":"Demoulin","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626004861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:01:34Z","timestamp":1793350894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626004861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":96,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1538783626004861"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.001","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of anticoagulants: from heparin to novel target-specific agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}